XML 47 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Segment Information (Tables)
 6 Months Ended
Oct. 31, 2014
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following tables summarize, for the periods indicated, operating results by reportable segment (in thousands):
 
 
 
 
Personalized Oncology Solutions
 
Translational Oncology Solutions
 
 
 
 
 
 
 
Three Months Ended October 31, 2014
 
(POS)
 
(TOS)
 
Unallocated Corporate Overhead
 
Consolidated
 
Net revenue
 
$
452
 
$
1,430
 
$
-
 
$
1,882
 
Direct cost of services
 
 
(745)
 
 
(943)
 
 
-
 
 
(1,688)
 
Sales and marketing costs
 
 
(423)
 
 
(611)
 
 
-
 
 
(1,034)
 
Other operating expenses
 
 
-
 
 
(1,142)
 
 
(864)
 
 
(2,006)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(820)
 
 
(820)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(716)
 
$
(1,266)
 
$
(1,684)
 
$
(3,666)
 
 
Three Months Ended October 31, 2013
 
Personalized Oncology Solutions
(POS)
 
Translational Oncology Solutions 
(TOS)
 
Unallocated Corporate Overhead
 
Consolidated
 
Net revenue
 
$
623
 
$
1,760
 
$
-
 
$
2,383
 
Direct cost of services
 
 
(726)
 
 
(696)
 
 
-
 
 
(1,422)
 
Sales and marketing costs
 
 
(423)
 
 
(213)
 
 
-
 
 
(636)
 
Other operating expenses
 
 
-
 
 
(673)
 
 
(877)
 
 
(1,550)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(476)
 
 
(476)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(526)
 
$
178
 
$
(1,353)
 
$
(1,701)
 
 
Six Months Ended October 31, 2014
 
Personalized Oncology Solutions
(POS)
 
Translational Oncology Solutions
(TOS)
 
Unallocated Corporate Overhead
 
Consolidated
 
Net revenue
 
$
792
 
$
3,001
 
$
-
 
$
3,793
 
Direct cost of services
 
 
(1,498)
 
 
(1,905)
 
 
-
 
 
(3,403)
 
Sales and marketing costs
 
 
(877)
 
 
(1,036)
 
 
-
 
 
(1,913)
 
Other operating expenses
 
 
-
 
 
(2,460)
 
 
(1,777)
 
 
(4,237)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(1,627)
 
 
(1,627)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(1,583)
 
$
(2,400)
 
$
(3,404)
 
$
(7,387)
 
 
Six Months Ended October 31, 2013
 
Personalized Oncology Solutions 
(POS)
 
Translational Oncology Solutions 
(TOS)
 
Unallocated Corporate Overhead
 
Consolidated
 
Net revenue
 
$
1,245
 
$
4,158
 
$
-
 
$
5,403
 
Direct cost of services
 
 
(1,470)
 
 
(1,566)
 
 
-
 
 
(3,036)
 
Sales and marketing costs
 
 
(754)
 
 
(460)
 
 
-
 
 
(1,214)
 
Other operating expenses
 
 
-
 
 
(1,063)
 
 
(1,534)
 
 
(2,597)
 
Stock- based compensation expense (1)
 
 
-
 
 
-
 
 
(1,028)
 
 
(1,028)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Segment profit (loss)
 
$
(979)
 
$
1,069
 
$
(2,562)
 
$
(2,472)
 
  
(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.